Endocrine therapy for premenopausal breast cancer patients, including tamoxifen (TAM), ovarian function suppression (OFS) and aromatase inhibitors (AIs), is based on lowering circulating estrogen levels. The gene discussed is CYP19A1; the disease is breast carcinoma.